Inhibitory effect of a prostaglandin E receptor subtype EP1 selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice

Cancer Letters

Volumn 156, Issue 1, 2000, Pages 57-61

  Watanabe, Kouji ^a   Kawamori, Toshihiko ^a   Nakatsugi, Seiichi ^a   Ohta, Toshihisa ^a   Ohuchida, Shuichi ^b   Yamamoto, Hiroshi ^b   Maruyama, Takayuki ^b   Kondo, Kigen ^b   Narumiya, Shuh ^c   Sugimura, Takashi ^a   Wakabayashi, Keiji ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Aberrant crypt foci; Azoxymethane; EP1 antagonist; ONO 8713; Prostaglandin

Indexed keywords

ONO 8713; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME ABERRATION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; AZOXYMETHANE; CINNAMATES; COLONIC NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; PRECANCEROUS CONDITIONS; RECEPTORS, PROSTAGLANDIN E;

EID: 18744435476     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00440-7     Document Type: Article

References (21)

1. Thun M.J., Namboodiri M.M., Heath C.W. Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325:1991;1593-1596.
2. Reddy B.S., Tokumo K., Kulkarni N., Aligia C., Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis. 13:1992;1019-1023.
3. Rao C.V., Rivenson A., Simi B., Zang E., Kelloff G., Steele V., Reddy B.S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 55:1995;1464-1472.
4. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
5. Kargman S.L., O'Neill G.P., Vickers P.J., Evans J.F., Mancini J.A., Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55:1995;2556-2559.
6. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:1995;3785-3789.
7. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
8. Rigas B., Goldman I.S., Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122:1993;518-523.
9. 2 in human colon cancer cells. Cancer Res. 58:1998;362-366.
10. Ushikubi F., Hirata M., Narumiya S. Molecular biology of prostanoid receptors; an overview. J. Lipid Mediat. Cell Signal. 12:1995;343-359.
11. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79:1999;1193-1226.
12. Bird R.P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 37:1987;147-151.
13. 3. Nature. 395:1998;281-284.
14. 1 in colon carcinogenesis. Cancer Res. 59:1999;5093-5096.
15. Kiriyama M., Ushikubi F., Kobayashi T., Hirata M., Sugimoto Y., Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122:1997;217-224.
16. Reddy B.S., Rao C.V., Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 56:1996;4566-4569.
17. Takahashi M., Fukutake M., Yokota S., Ishida K., Wakabayashi K., Sugimura T. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J. Cancer Res. Clin. Oncol. 122:1996;219-222.
18. Rao C.V., Newmark H.L., Reddy B.S. Chemopreventive effect of squalene on colon cancer. Carcinogenesis. 19:1998;287-290.
19. 2. Proc. Natl. Acad. Sci. USA. 96:1999;10501-10506.
20. 4-deficient mice. Biochem. Biophys. Res. Commun. 246:1998;7-12.
21. 4 triggers remodelling of the cardiovascular system at birth. Nature. 390:1997;78-81.